BioNxt Solutions Inc. Stock: price and insider trades · Canada
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 650,000 sharesOptionsTSXSEDI:4764112
- 100,000 shares@ CA$0.3361.5% of flowOptionsTSXSEDI:4759414
- 850,000 shares@ CA$0.33100.0% of flowOptionsTSXSEDI:4758504
- 150,000 shares@ CA$0.8078.5% of flowOptionsTSXSEDI:4758345
- 100,000 shares@ CA$0.3321.5% of flowOptionsTSXSEDI:4758344
- 20,000 shares@ CA$1.018338.5% of flowCommon SharesTSXSEDI:4724449
- 100,000 shares@ CA$0.5017.2% of flowCommon SharesTSXSEDI:4655587
- 100,000 shares@ CA$0.5017.0% of flowCommon SharesTSXSEDI:4652827
- 39,000 shares@ CA$0.658.7% of flowCommon SharesTSXSEDI:4652452
- 35,000 shares@ CA$0.627.4% of flowCommon SharesTSXSEDI:4649616
- 7,500 shares@ CA$0.651.7% of flowCommon SharesTSXSEDI:4649617
- 50,000 shares@ CA$0.508.6% of flowCommon SharesTSXSEDI:4649614
- 90,000 shares@ CA$0.5216.1% of flowCommon SharesTSXSEDI:4649615
- 56,000 shares@ CA$0.6710.8% of flowCommon SharesTSXSEDI:4622390
- 6,000 shares@ CA$0.662.5% of flowCommon SharesTSXSEDI:4622249
- 15,500 shares@ CA$0.8216.6% of flowCommon SharesTSXSEDI:4606531
- 28,500 shares@ CA$0.76728.6% of flowCommon SharesTSXSEDI:4606532
- 24,000 shares@ CA$0.8727.3% of flowCommon SharesTSXSEDI:4606533
- 25,000 shares@ CA$0.775.5% of flowCommon SharesTSXSEDI:4604436
- 1,500 shares@ CA$0.780.3% of flowCommon SharesTSXSEDI:4604437
- 24,000 shares@ CA$0.8727.4% of flowCommon SharesTSXSEDI:4592025
- 8,000 shares@ CA$0.872.0% of flowCommon SharesTSXSEDI:4592039
- 2,300 shares@ CA$0.8410.5% of flowCommon SharesTSXSEDI:4581910
- 2,000 shares@ CA$0.890.5% of flowCommon SharesTSXSEDI:4581909
- 10,000 sharesCommon SharesTSXSEDI:4566001
25 of 34 declarations
About BioNxt Solutions Inc.
BioNxt Solutions Inc. has no purchase: its 27 filings include 15 sales worth EUR 110,036, with a median of EUR 4,292, 11 option exercises and one filing of another kind. The three largest sales are by Wolfgang Stefan Probst (Director of Issuer), EUR 23,198 on December 12, 2025, and by Hugh Allison Douglas Rogers (Director of Issuer), EUR 13,459 on November 13, 2025 and EUR 12,876 on October 10, 2025.
Wolfgang Stefan Probst has 8 filings of which 6 sales, David Waterhouse 7 of which 4 sales, and Hugh Allison Douglas Rogers 6 of which 4 sales. Patrick Joseph Meagher (Director of Issuer and Senior Officer of Issuer) lodges 4 and Raimar Loebenberg 2.
Read moreShow less
Activity fits into two years: 21 filings in 2025 and 6 in 2026, published from June 13, 2025 to August 13, 2026, a median of 4 days after the trade. The 13 filings of the last twelve months count 8 sales. The Canadian healthcare company, listed in Toronto, is worth CAD 38,775,716, of which 5.3% is held by insiders.
